Futura who?19 Dec 2023 08:22
Well the Gerald Ratner moment on 16th September webinar when we were told that despite the terrific launch of Eroxon and the inking on US deal with Haleon, we will only break-even in 2024 and then move into profit in 2025, has literally decimated the share price. The share price was 50p on that day and despite extending the patent life we are 27p on the bid almost 50% down and the chart looks like a downhill ski run. What have the Board done about it publicly? Nothing, as they have gone to ground no doubt realising that they have screwed up and are acting like rabbits in headlights. What I cannot fathom out, as we are not provided with much information, is why the US is apparently so unattractive commercially? Are the assumptions that we will not launch until the end of 2024. If so, why? If not, why did we sign a deal which gives us so little value? One thing is certain and that is if there are no significant management changes here in the short term I will lose patience and head for the exit as it is as clear as night follows day that our CEO and CFO are not the calibre we deserve to monetise Eroxon. I am hoping that we are bought out but even a 100% premium from here would be disappointing so we can be relived that Lombard will have a major say in any corporate action. If you are reading this Mr Barder come out from your shell and tell shareholders what you are doing to deal with this slide and to justify your remuneration otherwise you will not survive at the next AGM.